コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 thromboembolism (VTE) in pregnant women with essential thrombocythemia.
2 e drug of choice for high-risk patients with essential thrombocythemia.
3 of patients with idiopathic myelofibrosis or essential thrombocythemia.
4 tudies of muscle-invasive bladder cancer and essential thrombocythemia.
5 n vitro in cells obtained from patients with essential thrombocythemia.
6 tic transformation between the 2 subtypes of essential thrombocythemia.
7 s lower in JAK2-mutated than in CALR-mutated essential thrombocythemia.
8 s 29% at 15 years in those with JAK2-mutated essential thrombocythemia.
9 specially to distinguish early-stage PV from essential thrombocythemia.
10 tment of myelofibrosis and polycythemia vera/essential thrombocythemia.
11 or the subtypes of 1.2 (95% CI, 1.0-1.6) for essential thrombocythemia, 1.4 (95% CI, 1.2-1.7) for pol
12 6%], and Swedish [28%]) in 161 patients with essential thrombocythemia, 145 patients with polycythemi
13 ven of 41 subjects developed overt MPD (8/11 essential thrombocythemia, 3/11 PV) after the diagnosis
14 , 4.6-5.9) for patients with MPNs (2628 with essential thrombocythemia, 3063 with polycythemia vera,
17 We studied biologic and clinical features of essential thrombocythemia according to JAK2 or CALR muta
19 surprising degree of clonal heterogeneity in essential thrombocythemia, although the clinical signifi
20 presenting with polycythemia vera than with essential thrombocythemia, an increased risk of thrombos
21 mutations were detected in 67% of those with essential thrombocythemia and 88% of those with primary
23 era (PV), large proportions of patients with essential thrombocythemia and idiopathic myelofibrosis,
24 h other myeloproliferative disorders such as essential thrombocythemia and idiopathic myelofibrosis.
25 athophysiology of platelet diseases, such as essential thrombocythemia and immune thrombocytopenia, a
26 V617F) in approximately 50% of patients with essential thrombocythemia and its presence has been asso
27 ticulin (CALR) gene are seen in about 30% of essential thrombocythemia and myelofibrosis patients.
28 consistent with the notion that JAK2-mutated essential thrombocythemia and polycythemia vera represen
31 es of polycythemia vera, and roughly half of essential thrombocythemia and primary myelofibrosis acqu
33 sted the possibility that polycythemia vera, essential thrombocythemia and primary myelofibrosis are
34 majority of patients with polycythemia vera, essential thrombocythemia and primary myelofibrosis has
35 ythemia vera and about half of patients with essential thrombocythemia and primary myelofibrosis) has
37 vera and approximately 50% of patients with essential thrombocythemia and primary myelofibrosis, it
38 in most individuals with polycythemia vera, essential thrombocythemia and primary myelofibrosis, the
39 vera and in approximately half of those with essential thrombocythemia and primary myelofibrosis.
40 icacy in the treatment of polycythemia vera, essential thrombocythemia and primary myelofibrosis.
41 d myeloproliferative leukemia (MPL)-negative essential thrombocythemia and primary myelofibrosis.
42 polycythemia vera and one-half of those with essential thrombocythemia and primary myelofibrosis.
43 derstanding of the molecular pathogenesis of essential thrombocythemia and related disorders, and off
44 ding the thrombogenic role of neutrophils in essential thrombocythemia and this might partly explain
46 erative neoplasms (MF > polycythemia vera or essential thrombocythemia) and that LCN2 was elaborated
47 with polycythemia vera, 12% of patients with essential thrombocythemia, and 0% of normal controls.
48 AK2 V617F as a risk factor for thrombosis in essential thrombocythemia, and have also shown a tight a
49 le in the pathogenesis of polycythemia vera, essential thrombocythemia, and idiopathic myelofibrosis.
50 neoplasms, including polycythemia vera (PV), essential thrombocythemia, and myelofibrosis (MF) (both
51 t of 726 individuals with polycythemia vera, essential thrombocythemia, and myelofibrosis and 252 637
52 was recently described in polycythemia vera, essential thrombocythemia, and myelofibrosis with myeloi
53 per patient in samples of polycythemia vera, essential thrombocythemia, and myelofibrosis, respective
54 ferative disorders (MPDs) polycythemia vera, essential thrombocythemia, and myeloid metaplasia with m
55 entory) to assess symptoms of myelofibrosis, essential thrombocythemia, and polycythemia vera among p
56 eoplasms (MPNs) including polycythemia vera, essential thrombocythemia, and primary myelofibrosis sho
57 ity of patients with polycythemia vera (PV), essential thrombocythemia, and primary myelofibrosis.
58 le in the pathogenesis of polycythemia vera, essential thrombocythemia, and primary myelofibrosis.
59 sorders (MPDs), including polycythemia vera, essential thrombocythemia, and primary myelofibrosis.
60 utation was identified in polycythemia vera, essential thrombocythemia, and primary myelofibrosis.
66 s well as approximately 50% of patients with essential thrombocythemia (ET) and idiopathic myelofibro
67 cythemia vera (PV) and in some patients with essential thrombocythemia (ET) and myeloid metaplasia/my
68 pal morbidity and mortality in patients with essential thrombocythemia (ET) and polycythemia rubra ve
69 alfa-2a (PEG-IFN-alpha-2a) in patients with essential thrombocythemia (ET) and polycythemia vera (PV
71 pean LeukemiaNet (ELN) response criteria for essential thrombocythemia (ET) and polycythemia vera (PV
73 main Ph(-) MPDs are polycythemia vera (PV), essential thrombocythemia (ET) and primary myelofibrosis
75 ecently discovered in patients with sporadic essential thrombocythemia (ET) and primary myelofibrosis
76 PL) mutations are specific to JAK2-unmutated essential thrombocythemia (ET) and primary myelofibrosis
77 tected in approximately 40% of patients with essential thrombocythemia (ET) and primary myelofibrosis
78 t that has recently been approved for use in essential thrombocythemia (ET) and related disorders.
79 characterized in polycythemia vera (PV) and essential thrombocythemia (ET) and shown to contribute t
81 lar mechanisms of polycythemia vera (PV) and essential thrombocythemia (ET) are challenging the tradi
83 mical resistance to aspirin in patients with essential thrombocythemia (ET) can be reversed by twice
84 with World Health Organization (WHO)-defined essential thrombocythemia (ET) compared with early/prefi
85 in patients with polycythemia vera (PV) and essential thrombocythemia (ET) has been associated with
87 myeloproliferative disorders (MPDs), such as essential thrombocythemia (ET) have increased risk of th
88 eas patients with polycythemia vera (PV) and essential thrombocythemia (ET) have moderately reduced s
91 e role of histopathology in the diagnosis of essential thrombocythemia (ET) is controversial, and the
93 in a significant proportion of patients with essential thrombocythemia (ET) lacking JAK2(V617F) or MP
94 ne were recently discovered in patients with essential thrombocythemia (ET) lacking the JAK2V617F and
96 ccurs in approximately half of patients with essential thrombocythemia (ET) or primary myelofibrosis
97 ed mutations of MPL exon 10 in patients with essential thrombocythemia (ET) or primary myelofibrosis
98 sponse to IFNalpha therapy in a cohort of 31 essential thrombocythemia (ET) patients with CALR mutati
99 umi et al and Rotunno et al demonstrate that essential thrombocythemia (ET) patients with calreticuli
100 ents, they are found in approximately 50% of essential thrombocythemia (ET) patients, suggesting that
103 7F)-positive cases rs9376092 associates with essential thrombocythemia (ET) rather than polycythemia
104 thway shows higher activity in patients with essential thrombocythemia (ET) than in polycythemia vera
105 s a wider mutational spectrum is detected in essential thrombocythemia (ET) with mutations in JAK2, t
106 ound in patients with myelofibrosis (MF) and essential thrombocythemia (ET) with nonmutated Janus kin
107 88 subjects: 30 with PV, 22 with SP, 14 with essential thrombocythemia (ET), 12 with myelofibrosis wi
108 of 183 patients with thrombocytosis-164 with essential thrombocythemia (ET), 19 with reactive thrombo
110 th MMM, 242 with polycythemia vera, 318 with essential thrombocythemia (ET), 88 with myelodysplastic
111 ms (MPNs), including polycythemia vera (PV), essential thrombocythemia (ET), and myelofibrosis (MF).
112 tion associated with polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosi
113 2V617F is associated with polycythemia vera, essential thrombocythemia (ET), and primary myelofibrosi
115 sms (MPNs) including polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosi
116 lasms (MPNs) include polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosi
117 neoplasms, including polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosi
118 e more common in polycythemia vera (PV) than essential thrombocythemia (ET), but their prevalence and
119 lycythemia vera (PV) is not a continuum from essential thrombocythemia (ET), that survival in ET is l
126 (MPNs) comprises several entities including essential thrombocythemia (ET); primary myelofibrosis (P
127 mited in their capacity to delineate clonal (essential thrombocythemia [ET]) from nonclonal (reactive
129 stratification, and molecular distinction of essential thrombocythemia from related disorders such as
130 olitinib is in late-phase clinical trials in essential thrombocythemia, in which it could fill an imp
131 entified in a family with autosomal dominant essential thrombocythemia, increased cell growth resulti
132 proliferative neoplasm, whereas CALR-mutated essential thrombocythemia is a distinct disease entity.
133 hemic, or fibrotic disease transformation in essential thrombocythemia is an infrequent occurrence wi
135 imary MF, post-polycythemia vera MF, or post-essential thrombocythemia MF were randomly assigned betw
136 ost-polycythemia vera myelofibrosis, or post-essential thrombocythemia myelofibrosis to receive oral
137 2 V617F-negative primary myelofibrosis, post-essential thrombocythemia myelofibrosis, or post-polycyt
138 loproliferative disorders polycythemia vera, essential thrombocythemia, myelofibrosis with myeloid me
139 vera, chronic idiopathic myelofibrosis, and essential thrombocythemia (n = 103) was similar to the p
140 lycythemia vera, n = 192, P = 2.9 x 10(-16); essential thrombocythemia, n = 78, P = 8.2 x 10(-9) and
141 lofibrosis or myelofibrosis (MF) preceded by essential thrombocythemia or polycythemia vera were enro
142 gic parameters of patients with JAK2-mutated essential thrombocythemia or polycythemia vera were rela
143 Approximately 50 to 60% of patients with essential thrombocythemia or primary myelofibrosis carry
144 y the JAK2V617F mutation, half of those with essential thrombocythemia or primary myelofibrosis do no
146 culin, have been found in most patients with essential thrombocythemia or primary myelofibrosis with
148 sequencing technology, further insights into essential thrombocythemia pathogenesis are likely close
150 eloproliferative neoplasms (MPNs), including essential thrombocythemia, polycythemia vera and primary
151 16.3), and 25.3 (SD, 17.2) for patients with essential thrombocythemia, polycythemia vera, and myelof
152 egative myeloproliferative neoplasms (MPNs), essential thrombocythemia, polycythemia vera, and primar
153 n January 1, 1994, and December 31, 2013, of essential thrombocythemia, polycythemia vera, myelofibro
154 evolved from antecedent polycythemia vera or essential thrombocythemia, presents many challenges to t
155 cardiovascular complications (mainly PV and essential thrombocythemia), prevention of hematological
156 osis (IMF) or end-stage polycythemia vera or essential thrombocythemia received allogeneic hematopoie
157 2 tyrosine kinase mutation (JAK2 (V617F)) in essential thrombocythemia, related myeloproliferative di
159 data imply that the aim of cytoreduction in essential thrombocythemia should be to keep the platelet
160 sis therapy, their role in polycythemia vera/essential thrombocythemia treatment is still being defin
162 g the myeloproliferation which characterizes essential thrombocythemia, whereas the phenotypic conseq
163 lso a biomarker of a subset of patients with essential thrombocythemia who are at increased risk of t
164 gic and molecular responses in patients with essential thrombocythemia who had not had a response to
166 molecular genetics of polycythemia vera and essential thrombocythemia, with an emphasis on JAK2V617F
WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。